AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
697 Burke Road
Suite 201
CamberwellVIC3124
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
1
Stocks News & Analysis
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
stocks
ASX energy producers: Energy prices rise sharply as global tensions flare, but long-term view unchanged
Our view on the chaotic energy markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.00 | 44.30 | -0.51% |
| CAC 40 | 7,701.95 | 67.36 | -0.87% |
| DAX 40 | 22,300.75 | 312.22 | -1.38% |
| Dow JONES (US) | 45,165.80 | 794.31 | -1.73% |
| FTSE 100 | 9,967.35 | 4.82 | -0.05% |
| HKSE | 24,542.78 | 409.10 | -1.64% |
| NASDAQ | 20,948.36 | 459.72 | -2.15% |
| Nikkei 225 | 51,061.63 | 2,311.44 | -4.33% |
| NZX 50 Index | 12,752.98 | 182.41 | -1.41% |
| S&P 500 | 6,370.69 | 106.47 | -1.64% |
| S&P/ASX 200 | 8,416.40 | 44.50 | -0.53% |
| SSE Composite Index | 3,884.34 | 29.38 | -0.75% |